Trial reportJournal of immunology (Baltimore, Md. : 1950)2019
Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity.
Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.Journal of neurology, neurosurgery, and psychiatry · 2026Trial
- The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD.Annals of clinical and translational neurology · 2026Article
- Neuromyelitis in a Patient with Rheumatoid Arthritis: A Case Report.Archives of Iranian medicine · 2024Article
- A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Remission of severe myasthenia gravis after autologous stem cell transplantation.Annals of clinical and translational neurology · 2023Article
- Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology.Acta neuropathologica · 2023Article
- MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity.JCI insight · 2023Article
- Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- The clinical need for clustered AChR cell-based assay testing of seronegative MG.Journal of neuroimmunology · 2022Article
- Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis.Frontiers in immunology · 2021Article
- Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.Frontiers in immunology · 2021Review
- Autoimmunity in 2019.Clinical reviews in allergy & immunology · 2020Review
- Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity.Journal of neurology · 2020Article
- Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.Frontiers in immunology · 2020Review
- Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.Brain : a journal of neurology · 2019Article
- Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Panos StathopoulosDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511.
Anne ChastreDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511.
Patrick WatersOxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 2JD, United Kingdom.
Sarosh IraniOxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX1 2JD, United Kingdom.
Miriam L FichtnerDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511.ORCID 0000-0002-0107-4103
Erik S BenottiDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511.ORCID 0000-0002-2037-9420
Joel M GuthridgeArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0002-9308-237X
Jennifer SeifertDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO 80045; and.
Richard J NowakDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511.
Jane H BucknerTranslational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA 98101.ORCID 0000-0002-9005-1885
V Michael HolersDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO 80045; and.
Judith A JamesArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.ORCID 0000-0002-9574-7355
David A HaflerDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511; kevin.oconnor@yale.edu david.hafler@yale.edu.
Kevin C O'ConnorDepartment of Neurology, Yale School of Medicine, New Haven, CT 06511; kevin.oconnor@yale.edu david.hafler@yale.edu.ORCID 0000-0002-7056-419X
Yale University · USOklahoma Medical Research Foundation · USUniversity of Colorado Denver · USUniversity of Oxford · GB
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2MRole of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7MTCR recognition of MHC class II peptide compexes in multiple sclerosisP01AI045757 · NIAID · DANA-FARBER CANCER INSTITUTE · PI WUCHERPFENNIG, KAI W · 1999 to 2017
$22.8MTransgenic / Knock-out mouse coreP01AI073748 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BEHAR, SAMUEL M · 2008 to 2019
$17.1MDefining the role of altered cytokine signaling pathways on autoimmunityU01AI101990 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI BUCKNER, JANE HOYT · 2012 to 2016
$12.1MOklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5MSNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7MPrevention Center U01: Early Targets for Antigen-Specific Tolerance Induction in Preclinical Rheumatoid ArthritisU01AI101981 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2012 to 2021
$6.2MRegulatory T Cells in Autoimmune DiseaseU19AI070352 · NIAID · YALE UNIVERSITY · PI HAFLER, DAVID A. · 2006 to 2011
$5.9MTreatment of Autoimmune Disease by Costimulatory Signal*U19AI046130 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI KHOURY, SAMIA J. · 1999 to 2007
$5.6MMechanisms of autoimmunity in myasthenia gravisR01AI114780 · NIAID · YALE UNIVERSITY · PI Kevin C O'Connor · 2016 to 2026
$4.7MDepartment of HealthNCATS NIH HHS UL1 TR001863NIAID NIH HHS P01 AI039671NIAID NIH HHS P01 AI045757NIAID NIH HHS P01 AI073748NIAID NIH HHS R01 AI114780NIAID NIH HHS R56 AI114780NIAID NIH HHS U01 AI101934NIAID NIH HHS U01 AI101981NIAID NIH HHS U01 AI101990NIAID NIH HHS U19 AI046130NIAID NIH HHS U19 AI070352NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P30 AR073750NIGMS NIH HHS U54 GM104938Wellcome TrustWellcome Trust 104079/Z/14/Z
Abstract
The aim of this study was to test whether autoantibodies against neurologic surface Ags are found in nonneurologic autoimmune diseases, indicating a broader loss of tolerance. Patient and matched healthy donor (HD) sera were derived from four large cohorts: 1) rheumatoid arthritis (RA) (
Indexed as
AutoantibodiesAutoantigensAutoimmune DiseasesB-LymphocytesFemaleHEK293 CellsHumansMaleMiddle AgedNerve Tissue ProteinsAutoantibodiesAutoantigensNerve Tissue Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.